Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2564-2568

  Baltch, Aldona L ^a,b   Smith, Raymond P ^a   Ritz, William J ^a   Bopp, Lawrence H ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; DALFOPRISTIN; GENTAMICIN; ORITAVANCIN; QUINUPRISTIN; TEICOPLANIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATION; COLONY FORMING UNIT; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0031662779     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2564     Document Type: Article

References (34)

1. Allen, N. E., J. N. Hobbs, Jr., and T. I. Nicas. 1996. Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic. Antimicrob. Agents Chemother. 40:2356-2362.
2. Allen, N. E., J. N. Hobbs, Jr., and D. L. LeTourneau. 1996. The role of ligand binding, dimerization and membrane interactions in the antibacterial action of glycopeptide antibiotics, abstr. C12, p. 36. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Andrew, J. H., M. C. J. Wale, L. J. Wale, and D. Greenwood. 1987. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J. Antimicrob. Chemother. 20:213-221.
4. Beauregard, D. A., D. H. Williams, M. N. Gwynn, and D. J. C. Knowles. 1995. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. 39:781-785.
5. Biavasco, F., C. Vignaroli, R. Lupidi, E. Manso, B. Facinelli, and P. E. Varaldo. 1997. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. 41:2165-2172.
6. Boylan, C. J., T. I. Nicas, D. A. Preston, D. L. Zeckner, B. J. Boyll, P. A. Raab, D. L. Mullen, N. J. Snyder, L. L. Zornes, R. E. Stratford, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1995. Efficacy of semisynthetic glycopeptides active against vancomycin-resistant enterococci in a mouse infection model, abstr. F255, p. 157. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Centers for Disease Control. 1993. Nosocomial enterococci resistant to vancomycin - United States. Morbid. Mortal. Weekly Rep. 45:597-599.
8. Cooper, G. L., A. Louie, A. L. Baltch, R. C. Chu, R. P. Smith, W. J. Ritz, and P. Michelsen. 1993. Influence of zinc on Pseudomonas aeruginosa susceptibilities to imipenem. J. Clin. Microbiol. 31:2366-2370.
9. Cooper, R. D. G., N. J. Snyder, M. J. Zweifel, M. A. Staszak, S. C. Wilkie, T. I. Nicas, D. L. Muller, T. F. Butler, M. J. Rodriguez, B. E. Huff, and R. C. Thompson. 1996. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J. Antibiot. 49:575-581.
10. Courvalin, P. 1990. Resistance of enterococci to glycopeptides. Antimicrob. Agents Chemother. 34:2291-2296.
11. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, Md.
12. Facklam, R. R., and M. D. Collins. 1989. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J. Clin. Microbiol. 27:731-734.
13. Fraise, A. P., J. Andrews, and R. Wise. 1997. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant Gram-positive organisms. J. Antimicrob. Chemother. 40:423-425.
14. Gaynes, R. P., D. H. Culver, T. G. Emori, et al. 1991. The National Nosocomial Infection Surveillance System, plans for the 1990's and beyond. Am. J. Med. 91(Suppl. 38):116-120.
15. Jett, B., L. Free, and D. F. Sahm. 1996. Factors influencing the Vitek Gram-Positive Susceptibility system's detection of vanB-encoded vancomycin resistance among enterococci. J. Clin. Microbiol. 34:701-706.
16. Johnson, A. P., A. H. C. Uttley, N. Woodford, and R. C. George. 1990. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin. Microbiol. Rev. 3:280-291.
17. Jones, R. N., M. S. Barrett, and M. E. Erwin. 1996. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob. Agents Chemother. 41:488-493.
18. Jones, R. N., H. S. Sader, M. E. Erwin, S. C. Anderson, and the Enterococcus Study Group. 1995. Emerging multiply resistant enterococci among clinical isolates. Diagn. Microbiol. Infect. Dis. 21:85-93.
19. Kenny, M. A., H. M. Pollock, B. H. Minshew, E. Casillas, and F. D. Schoenknecht. 1980. Cation components of Mueller-Hinton agar affecting testing of Pseudomonas aeruginosa susceptibility to gentamicin. Antimicrob. Agents Chemother. 17:55-62.
20. Lin, Y., R. E. Stratford, L. L. Zornes, W. L. Confer, V. Vasudevan, T. W. Jones, T. I. Nicas, D. A. Preston, C. J. Boylan, D. L. Zeckner, B. J. Boyll, P. A. Raab, N. J. Snyder, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1995. Non-clinical pharmacokinetics of LY333328, a semisynthetic glycopeptide antibiotic active against vancomycin-resistant enterococci, abstr. F254, p. 157. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
21. Moellering, R. C. 1992. Emergence of Enterococcus as a significant pathogen. Clin. Infect. Dis. 14:1173-1176.
22. Nagarajan, R. 1993. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J. Antibiot. 46:1184-1195.
23. National Committee for Clinical Laboratory Standards. 1995. Performance standards for antimicrobial susceptibility testing: sixth informational supplement. Document M100-S6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. National Committee for Clinical Laboratory Standards. 1992. Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M26-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
25. National Committee for Clinical Laboratory Standards. 1990. Approved standard M7-A2. Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically, 2nd ed., National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. Nicas, T. I., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1996. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 40:2194-2199.
27. Nicas, T. I., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J., Snyder, R. E. Stratford, and R. D. G. Cooper. 1995. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob. Agents Chemother. 39:2585-2587.
28. Novelli, A., T. Mazzei, S. Fallani, M. I. Cassetta, and S. Conti. 1997. In vitro postantihiotic effect of the semisynthetic glycopeptide LY 333328 on clinical gram-positive pathogens, abstr. F-16, p. 148. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
29. Schaberg, D. R., D. J. Culver, and R. P. Gaynes. 1991. Major trends in microbial etiology of nosocomial infection. Am. J. Mod. 90(Suppl. 3B):72S-75S.
30. Schwalbe, R. S., A. C. McIntosh, S. Qaiyumi, J. A. Johnson, R. J. Johnson, K. M. Furness, W. J. Holloway, and L. Steele-Moore. 1996. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. 40:2416-2419.
31. Schwalbe, R. S., and T. R. Iarocci. 1997. Establishment of a neutropenic mouse model to characterize activity of LY333328 against vancomycin-resistant enterococci, abstr. F-13, p. 148. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
32. Woodford, N., A. P. Johnson, D. Morrison, and D. C. E. Speller. 1995. Current perspectives on glycopeptide resistance. Clin. Microbiol. Rev. 8:585-615.
33. Yao, R. C., and L. W. Crandall. 1994. Glycopeptides: classification, occurrence and discovery, p. 1-29. In R. Nagarajan (ed.), Glycopeptide antibiotics. Marcel Dekker, Inc., New York, N.Y.
34. Zelenitsky, S., B. Booker, J. Karlowsky, D. Hoban, N. Laing, A. Kabani, M. Zeckel, and G. Zhanel. 1997. Synergistic activity of an investigational [sic] glycopeptide, LY333328, and once-daily gentamicin against vancomycin-resistant Enterococcus faecium (VRE) in a multiple dose in vitro pharmacodynamic model, abstr. F-9, p. 147. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.